Farletuzumab + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-Sensitive Ovarian Cancer in First Relapse
Conditions
Platinum-Sensitive Ovarian Cancer in First Relapse
Trial Timeline
Mar 19, 2015 → Aug 13, 2020
NCT ID
NCT02289950About Farletuzumab + Placebo
Farletuzumab + Placebo is a phase 2 stage product being developed by Eisai for Platinum-Sensitive Ovarian Cancer in First Relapse. The current trial status is completed. This product is registered under clinical trial identifier NCT02289950. Target conditions include Platinum-Sensitive Ovarian Cancer in First Relapse.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02289950 | Phase 2 | Completed |
Competing Products
4 competing products in Platinum-Sensitive Ovarian Cancer in First Relapse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| OSE2101 + Pembrolizumab 25 MG/ML [Keytruda] | Merck | Phase 2 | 52 |
| Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| AK112 low dose + Chemotherapy + Olaparib + AK112 high dose | Akeso | Phase 2 | 51 |
| ZL-2306(nirapairb) + Placebos | Zai Lab | Phase 3 | 72 |